# ATAC - Endometrial Sub-Protocol

> **NCT00814125** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 285 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anastrozole (Arimidex)
- **DRUG:** Tamoxifen (Nolvadex)
- **DRUG:** Nolvadex placebo
- **DRUG:** Arimidex placebo

## Key facts

- **NCT ID:** NCT00814125
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2009-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814125, "ATAC - Endometrial Sub-Protocol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00814125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*